Maynard Um
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)
-
-
-
-
-
-
-
Dynegy (DYN) Misses Q2 EPS by 33c
-
-
-
-
-
-
-
Dyne Therapeutics expands debt facility to $400M with Hercules Capital
-
-
-
-
-
-
-
Baird on Dyne Therapeutics (DYN): 'Positive on clinical progress and improved regulatory dynamic'
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Raised to $21 at Bernstein SocGen Group, we see risk-reward as favorable
-
466,309 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


